Scholar Rock (SRRK) to Release Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.01. During the same quarter in the previous year, the company posted ($0.47) EPS. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Stock Up 0.4 %

SRRK opened at $29.08 on Friday. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -13.10 and a beta of 0.47. The firm has a 50 day moving average price of $18.76 and a 200-day moving average price of $13.15. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $35.38. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36.

Insider Activity

In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the completion of the sale, the chief financial officer now owns 161,088 shares in the company, valued at approximately $4,278,497.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Scholar Rock news, insider Tracey Sacco sold 30,000 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares of the company’s stock, valued at $1,262,681.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Edward H. Myles sold 206,240 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $26.56, for a total value of $5,477,734.40. Following the transaction, the chief financial officer now owns 161,088 shares of the company’s stock, valued at approximately $4,278,497.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,415,340 shares of company stock worth $40,666,088 over the last ninety days. Corporate insiders own 19.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Scholar Rock in a research note on Monday, November 4th. Piper Sandler raised their target price on Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. BMO Capital Markets boosted their price target on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, October 11th. HC Wainwright raised their price objective on Scholar Rock from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $33.29.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.